![]() ![]() ![]() ![]() Goldman Sachs has a Buy rating on the shares of the company and a $70 price target.Īt last check, shares of Kite Pharma were up 0.13 percent at $55.73.įull ratings data available on Benzinga Pro.ĭo you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. If the Phase 1 precedents translates to Phase 2, the firm believes a FDA approval of KTE-C19 is likely. The firm expects to see durability of at least six months in the full presentation scheduled for December 3–6. Related Link: Kite Pharma's Initial ZUMA Data "Solid" Barclays Raises Target ToĪnalyzing the trial results, Goldman Sachs noted that ZUMA-1 phase 2 interim pivotal data showed a three-month CR rate of 33 percent. (NASDAQ: AMGN) CAR T collaboration and provide an overview of the second wave of KTE-C19 indications. Jefferies Biren Amin reiterated a Buy rating and 83. Great news from Kite Pharma - In Three-Year Follow-up in Relapsed/Refractory Mantle Cell Lymphoma, Tecartus Induced High Rates of. The analyst also expects to have more clarity on capacity at launch.Īdditionally, the analyst expects the company to disclose its first target from the Amgen, Inc. The European Commission has approved Gilead Science Inc (NASDAQ: GILD) company Kite Pharmas CAR T-cell therapy Tecartus (brexucabtagene autoleucel) for patients 26 years and above with relapsed. Kite Pharma Inc (NASDAQ: KITE ) hopes to seek regulatory approval next year for a treatment for a form of lymphoma, an analyst said Wednesday. Analyst Salveen Richter said she expects the company's chief compliance officer Shawn Tomasello to shed light on payor discussions, Kite's market research and the potential launch trajectory at the R&D day to be held in New York on October 18. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |